EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation

Chia-Yu Wang iD, Emiliano Melgar-Bermudez, Diana Welch, Kevin B Dagbay iD, Seemana Bhattacharya, Evan Lema, Tyler Daman iD, Olivia Sierra, Radina Todorova, Papa Makhtar Drame, Rosa Grenha, Ffolliott M Fisher und 5 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Chia-Yu Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Keros Therapeutics, Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Iron, Anemia, Inflammation, Bone Morphogenetic Protein Receptors, Type I. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as anemia impacts quality of life and potentially affects morbidity and mortality. The bone morphogenetic protein (BMP)‐SMAD pathway is crucial for hepcidin regulation. Here, we characterized a research antibody against BMP receptor ALK2, RKER‐216, and investigated its mechanism in suppressing hepcidin and improving anemia in acute/chronic inflammation. Additive effects of RKER‐216 and recombinant human erythropoietin (rhEPO) on erythropoiesis and iron utilization were also explored. We showed that RKER‐216 neutralized ALK2 activity by competing with the binding of BMP6. RKER‐216 reduced hepcidin transcription in Hep3B cells, and a subcutaneous dose of RKER‐216 at 3 mg/kg suppressed serum hepcidin and increased circulating iron for 3–4 days in wildtype mice. Moreover, RKER‐216 decreased hepcidin by inhibiting SMAD1/5/9 signaling in lipopolysaccharide‐mediated inflammation and liberated iron from the recycling pathway to alleviate anemia in mice with adenine‐induced chronic kidney disease (CKD), a mouse model of AI. Finally, RKER‐216 reversed iron‐restricted erythropoiesis in CKD mice and supplied the iron requirement for complete resolution of anemia when coupled with rhEPO in addressing AI. Our data support that ALK2 is a key hepcidin regulator and that a neutralizing ALK2 antibody has the potential to restore iron homeostasis as monotherapy or in combination with rhEPO to ameliorate AI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IronAnemiaInflammationBone Morphogenetic Protein Receptors, Type IActivin Receptors, Type IAnimalsMiceDisease Models, AnimalHepcidinsHumansRecombinant ProteinsErythropoietinSignal TransductionErythropoiesisMaleMice, Inbred C57BL

Stichwörter der Autor:innen

ALK2BMP‐SMADanemia of inflammationhepcidin regulationiron repletion

Substanzen

IronHepcidinsRecombinant ProteinsBone Morphogenetic Protein Receptors, Type IErythropoietinActivin Receptors, Type I

Autor:innen und Institutionen

  • Keros Therapeutics, Lexington, Massachusetts, USA.

ORCID-Profile: Chia-Yu Wang, Kevin B Dagbay, Tyler Daman, Lorena Lerner

Zitieren

APA

Wang, C. Y., Melgar-Bermudez, E., Welch, D., Dagbay, K. B., Bhattacharya, S., Lema, E., Daman, T., Sierra, O., Todorova, R., Drame, P. M., Grenha, R., Fisher, F. M., Grayson, D., Lerner, L., Cadena, S. M., Seehra, J., & Lachey, J. (2025). A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation. American Journal of Hematology. https://doi.org/10.1002/ajh.27578

Vancouver

Wang CY, Melgar-Bermudez E, Welch D, Dagbay KB, Bhattacharya S, Lema E, et al. A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation. American Journal of Hematology. 2025. doi:10.1002/ajh.27578

BibTeX
@article{Wang2025,
  author = {Wang, Chia-Yu and Melgar-Bermudez, Emiliano and Welch, Diana and Dagbay, Kevin B and Bhattacharya, Seemana and Lema, Evan and Daman, Tyler and Sierra, Olivia and Todorova, Radina and Drame, Papa Makhtar and Grenha, Rosa and Fisher, Ffolliott M and Grayson, Dena and Lerner, Lorena and Cadena, Samuel M and Seehra, Jasbir and Lachey, Jennifer},
  title = {A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27578}
}
Kostenlos starten →